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Abstract: Chlorhexidine gluconate (CHG) is a topical antiseptic used in a myriad of clinical 
settings. Recently, CHG baths have been shown to decrease multidrug-resistant organism 
acquisition and infections and catheter-associated bloodstream infections. The present study 
examined the effects of daily bathing with CHG on the recovery and antimicrobial   susceptibility 
of cultivable cutaneous bacteria. The objectives of this study were to (1) explore the effects 
of clinical CHG bathing on cultivable cutaneous bacteria, (2) study the relationship between 
CHG minimum inhibitory concentration and antimicrobial susceptibility of coagulase-negative 
staphylococci, and (3) demonstrate the feasibility of the approach so a more definitive study 
may be performed. Significant decreases in bacterial colony counts and phenotypic diversity 
occurred with greater CHG exposure. The findings also suggest an inverse relationship between 
CHG minimum inhibitory concentration and antimicrobial susceptibility. Larger prospective 
studies are necessary to fully investigate the clinical impact of CHG usage.
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Introduction
Chlorhexidine gluconate (CHG) is a topical antiseptic used in a myriad of clinical 
settings. Recently, CHG baths have been shown to decrease multidrug-resistant organ-
ism acquisition and infections and catheter-associated bloodstream infections.1,2
Limited in vitro data suggest that some organisms develop elevated minimum 
inhibitory concentrations (MICs) to CHG with continued exposure.3 In Staphylococcus 
aureus, the qacA plasmid-borne resistance determinant is associated with efflux of 
CHG from bacteria4 and with antimicrobial resistance.3,5–7 Clinical data are needed to 
better understand the extent to which regular clinical CHG exposure is associated with 
elevated CHG MICs and reduced susceptibility to other antimicrobials. Furthermore, 
most prior studies focus on qacA activity in S. aureus, although coagulase-negative 
staphylococci (CoNS) commonly cause catheter-associated infections.
The objectives of this study were to (1) explore the effects of clinical CHG   bathing 
on cultivable cutaneous bacteria, (2) study the relationship between CHG MIC and 
antimicrobial susceptibility of CoNS, and (3) demonstrate the feasibility of the approach 
so a more definitive study may be performed.
Materials and methods
In the authors’ hospital, Seattle Children’s Hospital (Seattle, WA), patients with central 
lines are “bathed” daily by wiping their skin, from the neck down, with a 2% CHG-
impregnated cloth (Sage Products, Inc, Cary, IL). Pediatric patients were eligible 
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for study enrollment if they were aged 2 months or older, 
hospitalized between November 2010 and April 2011, and 
scheduled to receive daily CHG baths.
Samples were obtained by rubbing a saline-moistened 
sterile nylon-flocked swab (Copan Diagnostics Inc, 
Murrieta, CA) over a 9 cm2 area of skin for 30   seconds. 
Patients were swabbed in the right axilla weekly until dis-
charge, and the same researcher performed the   swabbing 
each time. Swabs were vortexed in normal saline and 
aliquots were inoculated onto the following agars: 
sheep blood, chocolate, mannitol salt, MacConkey, and 
Sabouraud dextrose. Plates were incubated at 35°C and 
checked for growth by 48 hours; any growth was subcul-
tured and identified as CoNS, S. aureus, Streptococcus 
  pneumoniae, Enterococcus spp, viridans streptococci, 
group A   streptococci, Bacillus spp, diphtheroids, yeast, 
or gram-negative (no further analysis of gram-negative 
organisms).8 The total colony count of a swab was obtained 
from the blood agar plate.
CoNS isolates underwent antimicrobial susceptibility 
testing and were classified as susceptible or nonsuscep-
tible using Clinical and Laboratory Standards Institute 
recommendations.9 Antimicrobials tested were pen-
icillin (10 µg),   amoxicillin-clavulanate (20/10 µg), 
cefazolin (30 µg), cefoxitin (30 µg), ceftriaxone (30 µg), 
clindamycin (2 µg), erythromycin (15 µg), gentamicin 
(10 µg),   trimethoprim-sulfamethoxazole (1.25/23.75 µg), 
  ciprofloxacin (5 µg), rifampin (5 µg), linezolid (30 µg), and 
vancomycin (range 0.016–256 µg/mL). Vancomycin suscep-
tibility was determined by Etest® (bioMérieux, Inc, Durham, 
NC); susceptibility to all other antibiotics was determined 
by disk diffusion. CHG MIC testing was conducted using a 
96-well broth microdilution method.9 Quality control organ-
isms were included in each panel.
Polymerase chain reaction (PCR) amplification for 
qacA/B was performed with the GeneAmp® system (Applied 
Biosystems, Carlsbad, CA), using primers for sequences 
conserved between the two genes.10 To distinguish qacA from 
qacB – which does not encode a CHG efflux pump – initial 
qacA/B PCR products were digested with the AluI restriction 
enzyme; qacA and qacB fragments were detected by agarose 
gel electrophoresis.10 Appropriate positive and negative 
control isolates were used in each step.
Every swab obtained was categorized into one of the 
following CHG exposure groups: none (no CHG exposure), 
moderate (1–14 daily CHG baths), and heavy (.14 daily 
CHG baths). Some patients contributed swabs to more than 
one exposure group; therefore, analyses were based on CHG 
exposure of the swabs, rather than that of the patients. To 
minimize the possibility of one patient’s specimens heavily 
influencing the overall results, each patient was allowed 
to contribute only one swab per CHG exposure group for 
analyses of total colony and phenotype counts. If a patient 
had more than one swab in an exposure category, only 
the swab with the greatest CHG exposure was included. 
Similarly, each patient was allowed to contribute one CoNS 
isolate per CHG exposure category for analyses of CHG 
MIC. If a patient had more than one isolate in an exposure 
category, only the isolate with the highest CHG MIC was 
included. Lastly, for analyses of antimicrobial susceptibil-
ity versus CHG MIC, patients were allowed to contribute 
one CoNS isolate per CHG MIC category (#1 µg/mL   
or $2 µg/mL).
The authors compared bacterial colony counts per 
swab and number of bacterial phenotypes per swab across 
exposure groups using the Kruskal-Wallis test. The pres-
ence of antimicrobial susceptibility across exposure groups 
was evaluated using Fisher’s exact test. Statistical analyses 
were performed using Stata (v 10.0; StataCorp LP, College 
Station, TX).
Results
Twenty-four patients were enrolled in the study. An equal 
number of male and female participants were involved, 
and participants had a mean age of 5.7 years (range from 
2 months to 19 years). Ultimately, four, fifteen, and ten 
swabs and three, eleven, and four individual CoNS isolates 
were included in the “none,” “moderate,” and “heavy” CHG 
exposure groups, respectively (Table 1). In the moderate and 
heavy exposure groups, the mean number of days receiving 
Table 1 Chlorhexidine gluconate (CHG) exposure versus measured outcomes
CHG exposure Swabs  
(n)
Bacterial colony  
count per swaba
Bacterial phenotypes  
per swab (n)a
CoNS  
isolates (n)
CHG MIC50   
(μg/mL)a
None 4 5145 (15–12 870) 2 (1–3) 3 1 (1–2)
Moderate (1–14 CHG baths) 15 15 (0–30 750) 1 (0–3) 11 1 (0.5–2)
Heavy (.14 CHG baths) 10 0 (0–7500) 0 (0–1) 4 1.5 (1–4)
Notes: aMedian values provided; numbers in parentheses reflect range values.
Abbreviations: CoNS, coagulase-negative staphylococci; MIC50, median minimum inhibitory concentration.
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Table 2 Comparison of antimicrobial susceptibility in isolates with 
a minimum inhibitory concentration of chlorhexidine gluconate 
(CHG MIC) #1 µg/mL and isolates with a CHG MIC $2 µg/mL
Antimicrobial  
agent
% susceptible to specified agenta P-valueb
CHG  
MIC # 1 μg/mL  
(n = 11)
CHG  
MIC $ 2 μg/mL   
(n = 5)
Amoxicillin- 
clavulanate
100 80 0.31
Cefoxitin 72 20 0.11
Cefazolin 100 20 0.003
Ceftriaxone 72 40 0.30
Ciprofloxacin 100 20 0.003
Clindamycin 91 20 0.01
Erythromycin 45 20 0.59
Gentamicin 100 40 0.02
Penicillin 18 20 0.99
Trimethoprim- 
sulfamethoxazole
72 20 0.11
Notes: aAll isolates were susceptible to vancomycin, linezolid, and rifampin; bfrom 
Fisher’s exact test.
CHG baths was 7.5 (range 1–14) and 51.6 (range 17–139), 
respectively (data not shown).
Median bacterial colony count per swab decreased 
from 5145 (range 15–12, median 870) to 15 (range 0–30, 
median 750) to 0 (range 0–7500) for the “none,” “moderate,” 
and “heavy” CHG exposure groups, respectively (P = 0.03). 
The median number of phenotypically different bacteria per 
swab also decreased across exposure groups: 2 (range 1–3), 
1 (range 0–3), and 0 (range 0–1), respectively (P = 0.02) 
(Table 1).
The median CHG MIC was 1 µg/mL for both low and mod-
erate CHG exposure groups (range 1–2 and 0.5–2 µg/mL, 
respectively) and 1.5 µg/mL (range 1–4 µg/mL) for the heavy 
exposure group (P = 0.35) (Table 1).
All CoNS isolates were susceptible to vancomycin, 
linezolid, and rifampin. Except for penicillin, antimicrobial 
susceptibility was more frequent in isolates in the lower CHG 
MIC group (MIC #1 µg/mL) than in the higher CHG MIC 
group (MIC $2 µg/mL) (Table 2). Eighty percent of isolates 
in the higher MIC group were found to be resistant to three 
or more antimicrobials, compared with only 27% of isolates 
in the lower MIC group (P = 0.11).
Of 17 tested CoNS isolates, eleven (65%) carried 
qacA/B. Ten of these isolates carried qacA specifically; 
AluI digestion was unsuccessful for one PCR product. 
qacA was detected in 100% of isolates in the higher 
CHG MIC group and in 45% of isolates in the lower 
MIC group (P = 0.09); 50% of qacA-positive isolates had 
CHG MICs $2 µg/mL.
Discussion
In a sample of pediatric patients with central lines and 
receiving daily CHG baths, greater CHG exposure was 
associated with lower colony counts of cultivable cutaneous 
bacteria and fewer different bacterial phenotypes. CoNS 
isolates with elevated CHG MICs were significantly less 
susceptible to several antimicrobials.
With increasing clinical use of CHG, there is concern 
that organisms may develop reduced susceptibility to the 
antiseptic and to other antimicrobials.3 A slight increase was 
observed in the median CHG MIC of cutaneous CoNS for the 
highest exposure group, but the difference was not significant. 
Similarly, while qacA was detected more frequently in CoNS 
with higher CHG MICs, the difference was not significant. 
However, it was found that the frequency of antimicrobial 
nonsusceptibility was significantly higher among CoNS with 
higher CHG MICs, suggesting an association between CHG 
MIC and resistance determinant(s) in CoNS. Prior studies 
most clearly demonstrate plasmid-based linkages between 
qacA/B and beta-lactamase genes.5,6 Another possible expla-
nation is that antimicrobial resistance is, in part, mediated 
by the QacA efflux pump.
This study was limited by its observational design and 
small convenience sample. The small sample size limited 
the ability to detect significant differences in median CHG 
MIC and presence of qacA among the different exposure 
groups. Nevertheless, this study is unique in its emphasis 
on clinical CHG use and suggests important hypotheses for 
future confirmatory studies.
Conclusion
The authors observed significant decreases in cultivable 
cutaneous bacterial colony counts and the number of phe-
notypes with increased CHG exposure. While the data did 
not demonstrate a clear association between CHG exposure 
and CHG MICs, the findings support an inverse relationship 
between CHG MIC and antimicrobial susceptibility in CoNS. 
Larger prospective studies are necessary to fully investigate 
the clinical impact of CHG usage.
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